Antibodies that bind to tl1a and their uses

Abstract

The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.

1 - 12 . (canceled) 
     
     
         13 . A humanized antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56, wherein the antibody or fragment thereof comprises a heavy chain variable framework region that is the product of or derived from human gene IGHV1-2*01 (SEQ ID NO: 3) and wherein the heavy chain variable framework region comprises at least one amino acid modification from the corresponding heavy chain variable framework region of a corresponding murine antibody. 
     
     
         14 . The antibody or fragment thereof of  claim 13 , wherein the antibody or fragment thereof comprises a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 16 and wherein the heavy chain variable framework region comprises at least one amino acid modification from the corresponding heavy chain variable framework region of a corresponding murine antibody. 
     
     
         15 . The antibody or fragment thereof of  claim 13 , wherein the amino acid modification comprises an amino acid substitution at an amino acid position selected from the group consisting of 37, 48, 50, 67, 69, 71 and 75, wherein the amino acid position of each group member is indicated according to the Kabat numbering. 
     
     
         16 . The antibody or fragment thereof of  claim 15 , wherein the amino acid modification comprises an amino acid substitution selected from the group consisting of 37A, 48I, 50E, 67A, 69L, 71V and 75S, wherein the amino acid position of each group member is indicated according to the Kabat numbering. 
     
     
         17 - 23 . (canceled) 
     
     
         24 . A humanized antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56, wherein the antibody or fragment thereof comprises a light chain variable framework region that is the product of or derived from human gene IGKV1-33*01 (SEQ ID NO: 8) and wherein the light chain variable framework region comprises at least one amino acid modification from the corresponding framework region of the light chain variable region of a corresponding murine antibody. 
     
     
         25 . A humanized antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56, wherein the antibody or fragment thereof comprises a light chain sequence comprising the amino acid sequence of SEQ ID NO: 17 and wherein the light chain variable framework region comprises at least one amino acid modification from the corresponding light chain variable framework region of the corresponding murine antibody. 
     
     
         26 . The antibody or fragment thereof of  claim 24 , wherein the amino acid modification comprises an amino acid substitution at an amino acid position selected from the group consisting of 5 and 34, wherein the amino acid position of each group member is indicated according to the Kabat numbering. 
     
     
         27 . The antibody or fragment thereof of  claim 26 , wherein the amino acid modification comprises an amino acid substitution selected from the group consisting of 5N and 34S, wherein the amino acid position of each group member is indicated according to the Kabat numbering. 
     
     
         28 - 67 . (canceled) 
     
     
         68 . The antibody or fragment thereof of  claim 14 , wherein the amino acid modification comprises an amino acid substitution at an amino acid position selected from the group consisting of 37, 48, 50, 67, 69, 71 and 75, wherein the amino acid position of each group member is indicated according to the Kabat numbering. 
     
     
         69 . The antibody or fragment thereof of  claim 68 , wherein the amino acid modification comprises an amino acid substitution selected from the group consisting of 37A, 48I, 50E, 67A, 69L, 71V and 75S, wherein the amino acid position of each group member is indicated according to the Kabat numbering. 
     
     
         70 . The antibody or fragment thereof of  claim 25 , wherein the amino acid modification comprises an amino acid substitution at an amino acid position selected from the group consisting of 5 and 34, wherein the amino acid position of each group member is indicated according to the Kabat numbering. 
     
     
         71 . The antibody or fragment thereof of  claim 70 , wherein the amino acid modification comprises an amino acid substitution selected from the group consisting of 5N and 34S, wherein the amino acid position of each group member is indicated according to the Kabat numbering.